PANCREAS
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma – a phase II study
CASE 4214 |14-1289
View full trial information
SOLID TUMORS
A Phase 1b Study of PF-05082566 in Combination with Mogamulizumab (Kw-0761) in Patients with Advanced Solid Tumors
PFIZ 1Y15 | 15-667
View full trial information
RENAL
A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma
GENE 1815 | 15-361
View full trial information
LUNG
Phase II study of MK-3475 as Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (SCLC) Patients
KCC 1515| 15-978
View full trial information
HEAD & NECK
Phase I Dose Escalation Study of Stereotactic Body Radiotherapy for p16 Negative Squamous Cell Carcinoma of the Head and Neck in High Risk Patients Who are Ineligible/Refuse Standard of Care Therapy
CASE 8314 | 15-006
View full trial information
LEUKEMIA, ACUTE MYELOID (AML)
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation
AGSP 1Z14 | 15-124
View full trial information
TELANGIECTASIA VASCULAR ECTASIA
A Phase I single arm study to assess the safety and efficacy of Pomalidomide in patients with bleeding due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia
CASE 4Z14 | 14-786
View full trial information
SOLID TUMOR/LYMPHOMAS
NCI-MATCH Trial
This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients’ tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor’s particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.
EAY131-CCF
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
